Update on Ibrutinib

摘要

SO Several agents are currently being evaluated in clinical trials whose mechanism of action is inhibition of the B-cell receptors (BCRs). A chronic lymphocytic leukemia (CLL) cell is a B cell, and when the B-cell receptor on either a normal B cell or a malignant B cell is ligated, that cell receives a very strong survival and proliferative signal. In B-cell malignancies, interference with that signaling could very well have a laudatory effect on the disease. As with other inhibitors of the BCR pathway, ibrutinib causes rapid nodal reduction and rapid increase in lym-phocytosis, which returns to baseline over time. Ibrutinib is a first-in-class specific inhibitor of Bruton's tyrosine kinase (BTK), which is known to be expressed in CLL, small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.